Laboratory of Vascular Pathology and Regeneration, School of Clinical Sciences-Regenerative Medicine Section, University of Bristol, Bristol, England, UK.
Vascul Pharmacol. 2012 May-Jun;56(5-6):267-79. doi: 10.1016/j.vph.2012.03.007. Epub 2012 Apr 2.
Stem cell (SC) therapy represents a big hope for treating unmet clinical needs, including in the context of cardiovascular disease. The abilities of embryonic SC (ESCs) to self-renew indefinitely and to differentiate in all the three germ layers make these SCs very attractive for both basic science investigations and clinical therapies. ESCs can generate vascular endothelial and mural cells to be used for transplantation and to create engineered organs. Moreover ESC can be used to mimic developmental vasculogenesis and angiogenesis in vitro. However, additional studies are needed to improve vascular differentiation protocols of ESCs. This review focuses on ESCs and the technologies allowing for their differentiation into mesoderm and vascular lineage. Moreover, the potential of ESC-derived vascular cells for clinical cardiovascular therapies and strategies to improve ESC engraftment efficiency are discussed.
干细胞（SC）疗法代表了治疗未满足的临床需求的巨大希望，包括心血管疾病的治疗。胚胎干细胞（ESCs）的自我更新能力和在所有三个胚层中分化的能力使这些干细胞非常有吸引力，既可以用于基础科学研究，也可以用于临床治疗。ESCs 可以产生血管内皮细胞和血管壁细胞，用于移植和制造工程器官。此外，ESC 可用于模拟体外发育血管生成和血管生成。然而，还需要进一步的研究来改进 ESCs 的血管分化方案。本综述重点介绍了 ESCs 及其分化为中胚层和血管谱系的技术。此外，还讨论了 ESC 衍生的血管细胞在临床心血管治疗中的应用以及提高 ESC 移植效率的策略。
